When a foreign pharmaceutical company conducts clinical trials in the Japanese population in Japan to obtain approval for a medicinal product from the Health Authority in Japan, MHLW (Ministry of Health, Labor and Welfare) a clinical development strategy is required to obtain Japanese data for J-NDA filing for the following cases.
Fill the form below to download the White Paper
